Empagliflozin, a sodium-glucose cotransporter 2 inhibitors (SGLT2-I) initially developed for managing type 2 diabetes mellitus (T2DM), has recently garnered significant attention for its potential cardiovascular benefits beyond glycemic control.5 Clinical trials such as the EMPA-REG outcome trial have remarkably reduced cardiovascular mortality, heart failure hospitalization, and adverse cardiac events in patients with T2DM receiving empagliflozin. This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.